The bill mandates a review of anti-obesity medications, specifically including GLP-1 agonists, by the Department of Health and Human Services (HHS) and the Department of Administrative Services (DAS) for the medical assistance program and health insurance plans for state employees. The review will assess the effectiveness of these medications in relation to weight loss, their impact on comorbidities, potential cost savings from deferred medical procedures, recommended eligibility requirements, and any associated short-term and long-term costs of coverage.

HHS and DAS are required to compile their findings and submit a report to the General Assembly by January 5, 2026. This report will include proposed eligibility requirements and a detailed analysis of the costs associated with the coverage of anti-obesity medications. The bill aims to ensure that state health programs are informed by comprehensive evaluations of the medications' effectiveness and financial implications.